Acadia Pharmaceuticals surged over 150% in mid-morning trading after the company said its Pimavanserin drug for Parkinson's disease succeeded in meeting the primary goal and key secondary goals of a Phase III trial. In the study, which evaluated the efficacy, tolerability and safety of Pimavanserin in patients with Parkinson's disease psychosis, or PDP, Acadia said Pimavanserin met the primary endpoint of the trial by demonstrating highly significant antipsychotic efficacy as measured using the 9-item SAPS-PD scale. In addition, the drug met the secondary endpoint for motoric tolerability and clinical benefits were observed in all exploratory efficacy measures with significant improvements in nighttime sleep, daytime wakefulness and caregiver burden. Roger G. Mills, M.D., Acadia's EVP of Development, commented that "benefits of Pimavanserin were seen by patients, caregivers and investigators, as well as the independent raters." Acadia said it will continue ongoing preparations for a confirmatory Phase III trial, which will use the same design. Acadia is trading up $3.54, or 153.48%, to $5.82 in mid-morning trading.
- Pharmaceuticals & Drug Trials
- Acadia Pharmaceuticals